Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down – Time to Sell?

Posted by Brian Himes on Jun 17th, 2026

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $34.65, but opened at $33.27. Collegium Pharmaceutical shares last traded at $34.3540, with a volume of 130,572 shares changing hands.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on COLL. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Finally, Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $57.50.

View Our Latest Stock Report on Collegium Pharmaceutical

Collegium Pharmaceutical Stock Down 0.7%

The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The stock has a market capitalization of $1.12 billion, a P/E ratio of 16.87 and a beta of 0.74. The stock’s fifty day simple moving average is $34.08 and its two-hundred day simple moving average is $40.34.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. During the same period in the previous year, the firm posted $1.49 EPS. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. As a group, research analysts expect that Collegium Pharmaceutical, Inc. will post 6.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the business. Group One Trading LLC bought a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd grew its holdings in Collegium Pharmaceutical by 205.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 427 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $61,000. PNC Financial Services Group Inc. grew its holdings in Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 418 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 318 shares during the last quarter.

Collegium Pharmaceutical Company Profile

(Get Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.